Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2022
Reporting Period: Single event date (March 8, 2022)
This filing serves as a Regulation FD disclosure regarding an upcoming corporate presentation. The company is an emerging growth company incorporated in British Columbia, Canada, with common shares trading on The Nasdaq Stock Market LLC under the symbol "INM".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces a scheduled presentation by company leadership.
Guidance, Outlook, and Management Commentary
- Event Announcement: Eric A. Adams, President and Chief Executive Officer, is scheduled to present at the 34th Annual Roth Conference.
- Event Dates: March 13-15, 2022.
- Disclosure Status: The information, including the news release (Exhibit 99.1), is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the news release (Exhibit 99.1) for specific details regarding the Roth Conference presentation.
- Confirm the company's status as an emerging growth company and its implications for financial reporting standards.
- Review subsequent filings for any financial data or strategic updates that may have been discussed during the March 13-15, 2022 conference.